Navigation Links
sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
Date:4/28/2011

demics Vaccines

81

-14.1%Other Vaccines

35

-8.3%TOTAL602-38.3%First-quarter net sales of Sanofi Pasteur MSD (not consolidated by sanofi-aventis), the joint venture with Merck & Co. in Europe, were euro 139 million, down 22.6% on a reported basis, reflecting lower sales of Gardasil® (euro 43 million, down 27.7% on a reported basis) and pediatric vaccines.

Animal HealthAs a result of the mutual decision of sanofi-aventis and Merck to terminate their agreement to form a new animal health joint venture in animal health business and in accordance with IFRS 5.36, Merial assets / liabilities are no longer classified as "Assets held for sale or exchange / Liabilities related to assets held for sale or exchange" and Merial result is included in income from continuing operations. Consequently sales generated by Merial are consolidated in Group sales.

First-quarter net sales of Merial totaled euro 594 million, an increase of 11.5%. Sales of companion animals were sustained by the Frontline® family which reached sales of euro 270 million, up +15.1% led by the success of the spring campaign in the U.S. The good performance of this brand in the U.S. (Frontline® family sales in the U.S. were up 24.5%) largely offset the impact of Frontline® branded generics in Europe. Sales of production animals were driven by the avian segment boosted by the success of the vaccine Vaxxitex® (up 62%). Veterinary Public Health recorded a strong quarter due to sales of foot-and-mouth disease and rabies vaccines. First-quarter sales of Merial were up 13.5% in the U.S. (euro 259 million) and up 24.7% in Emerging Markets (euro 116 million).

A new combination product, Certifect®, which eliminates fleas and ticks within 24h on dogs is expected to be launched in the U.S. in Q2 2011.

Net sales by geographic region(millions of euros)

Q1 2011Change at constant exc
'/>"/>

SOURCE sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
2. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
3. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
5. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
8. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
9. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
10. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
11. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... HILDEN , Germany ... 2014 , ... Begleitdiagnostikums, das auf Basis genomischer Daten aus Plasmaproben ... mit nicht-kleinzelligem Lungenkrebs eingesetzt werden kann  ... zugelassenem  therascreen   EGFR Kit und soll auf Rotor-Gene ...
(Date:7/28/2014)... and LONDON , July ... Collaboration aims to create and commercialize companion diagnostic using ... of IRESSA  for non-small cell lung cancer patients  ... therascreen   EGFR test and is planned to run on Rotor-Gene Q, ... Project enabled by AstraZeneca master framework agreement adds ...
(Date:7/28/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Monday, August 4, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Monday, August 4 1:30 ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2
... 2007 - Cytogen,Corporation (NASDAQ: CYTO) reported updated ... evaluating QUADRAMET(R) (samarium Sm-153,lexidronam injection) in combination ... with relapsed,multiple myeloma. Data from 33 patients ... 1 Trial of Bortezomib (Vel) and Samarium,(Sam) ...
... achieved with VELCADE, lenalidomide,and dexamethasone , ,KOS, ... (Nasdaq: MLNM) today reported on the,presentation of ... based,therapies that showed consistently high survival and ... newly diagnosed,multiple myeloma (MM) patients. These data ...
Cached Medicine Technology:Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8
(Date:7/28/2014)... Washington, DC (PRWEB) July 28, 2014 ... beyond, many are looking to private exchanges. “Private ... the August 6 webinar from Atlantic Information Services, will ... insurers’ private exchange strategies for the future. , Barbara ... from PwC with extensive experience in the private exchange ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 According to the ... is a comprehensive guide that will help people get rid ... readers all the necessary information about heartburn and acid reflux. ... truth about heartburn , and risk factors for reflux disease. ... will help people get rid of symptoms of reflux disease ...
(Date:7/28/2014)... 2014 Building a sense of neighborhood ... Where personal outdoor space is not possible, building ... fun and exercise outside is important. That’s why ... quality commercial playground equipment from APCPLAY. , Old Buckingham ... Virginia. It is an historic tourist location of one ...
(Date:7/28/2014)... Los Angeles, Calif., July 27, 2014 - (PRWEB) July 28, ... world title in 12 months by earning the Masters Champion ... July 20, proving that age is no obstacle for this ... and win at the event hosted by the International Pole ... 10 to 63, traveling from 30 countries, took part in ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Dr. Alan Xenakis, ... “DOC X MD Funny Feelings.” The new book, DOC ... Feelings in a unique story telling style with humor and ... and motivational. The reader will find answers to those age-old ... running water make people pee? Why do mosquitoes bite some ...
Breaking Medicine News(10 mins):Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Playground Creates Outdoor Fun for Community at Old Buckingham Station at Midlothian Village (VA) with APCPLAY© 2Health News:Inspiring Senior Athlete Lands Third World Title in One Year 2Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2
... doing the rounds that global warming in the East ... A novel research by an international team places ... malaria’s spread, along with other factors like drug and ... University of Michigan theoretical ecologist Mercedes Pascual, has contributed ...
... with danger, is also the color of blood, signaling perpetuation ... of blood on a daily basis to cater to patients ... Sunderland have set the ball rolling, campaigning and urging people ... the run-up to Easter. ,Take the case of ...
... suggests that patients on the newer medications for diabetics ... spent between $920 and $1,760 less on annual total ... lead author and the Merrell Dow professor of pharmacy ... of medical records data on patients who took thiazolidinediones ...
... between widely used childhood medicines and the risk of developing ... allergies, expose the kids to pets and dirt early. The ... is known as the hygiene hypothesis. , It ... fields and farm animals, leaves people more susceptible to a ...
... review of several studies conducted on cancer-causing chemicals has ... babies as a consequence of exposure to organochlorines//. Pesticides ... such chemicals and may be passed on to humans ... it can be indirectly passed on to human beings ...
... cancer is one of the deadliest diseases in UK. Symptoms ... a need to rush to the loo//. ,Hence ... to increase awareness about prostate cancer. Prostate cancer kills 220 ... UK. ,Mr Campbell has won the support ...
Cached Medicine News:Health News:New Diabetic Drugs More Effective than Older Ones 2Health News:A Sneak Preview of Human’s Susceptibility to Auto Immune Disease, Allergy, Asthm 2Health News:Parents Concerned About Pesticide And Cancer Risk To Babies 2
The new Inferior Medial Orbital Rim Implant (IMORI) provides surgeons with an excellent alternative for patients with a deficient or recessed "tear trough" area often characterized as a look of fatig...
Flattened points in vertical plane, straight shafts, cross action, round handle....
Phaco chopper delicate rounded tip....
Karate chopper, spear shaped for ease of insertion into the nucleus....
Medicine Products: